CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

Abstract Introduction Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cogni...

Полное описание

Библиографические подробности

Главные авторы:	Nathan Herrmann, Zahinoor Ismail, Rhonda Collins, Philippe Desmarais, Zahra Goodarzi, Alexandre Henri‐Bhargava, Andrea Iaboni, Julia Kirkham, Fadi Massoud, Andrea Moser, James Silvius, Jennifer Watt, Dallas Seitz
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2022-01-01
Серии:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Предметы:	cholinesterase inhibitor memantine cognitive enhancer dementia deprescribing discontinuation
Online-ссылка:	https://doi.org/10.1002/trc2.12099
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!